Loading...
Regencell Bioscience Holdings Limited
RGC•NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$695.00
$70.05(11.21%)
Regencell Bioscience Holdings Limited (RGC) Financial Performance & Statements
Review Regencell Bioscience Holdings Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
24.50%
↑ 24.50%
Net Income Growth
26.73%
↑ 26.73%
Operating Cash Flow Growth
19.37%
↑ 19.37%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-25.23%
↓ 25.23%
ROIC
-29.44%
↓ 29.44%
Regencell Bioscience Holdings Limited (RGC) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Regencell Bioscience Holdings Limited stock.
| Metric | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $769687.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$769687.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $581483.00 | $242.00 | $242.00 | $231455.00 |
| SG&A Expenses | $1.84M | $914.00 | $914.00 | $1.84M |
| Operating Expenses | $2.42M | $1156.00 | $1156.00 | $2.07M |
| Total Costs & Expenses | $2.42M | $1156.00 | $1156.00 | $2.84M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $247540.00 | $73.00 | $73.00 | $769687.00 |
| EBITDA | -$2.18M | -$2.19M | -$1.08M | -$1.98M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$2.42M | -$1156.00 | -$1156.00 | -$2.84M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $247543.00 | -$1.03M | -$1.09M | $97063.00 |
| Income Before Tax | -$2.18M | -$1093.00 | -$1093.00 | -$2.75M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $57887.00 | -$119271.00 | -$60.00 | -$103334.00 |
| Net Income | -$2.24M | -$1033.00 | -$1033.00 | -$2.64M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.17 | -$0.00 | -$0.08 | -$0.20 |
| Diluted EPS | -$0.17 | -$0.00 | -$0.08 | -$0.20 |
| Weighted Avg Shares Outstanding | $13.01M | $13.01M | $13.01M | $13.01M |
| Weighted Avg Shares Outstanding (Diluted) | $13.01M | $13.01M | $13.01M | $13.01M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan